About US
Contact us
-
Johnson & Johnson says Puerto Rico plants 'fared well' in Maria but 'intermittent' shortages possibleIn the wake of the devastating Hurricane Maria in Puerto Rico, Johnson & Johnson executives say the company's manufacturing facilities "fared well" and are getting back up to full speed. "Int2017/10/11
-
Generics squeeze forces Novartis Colorado plant close, imperiling 450 jobsSome drugmakers are responding to industrywide generics pricing pressure by bulking up via M&A, but not Novartis. The Swiss company's Sandoz unit plans to scale back or nix production of some g2017/10/11
-
Biotech CDMO iBio teams with Aethlon to provide recombinant GNAiBio, a CDMO that focuses on plant-based biotechnology, said it reached an agreement to support Aethlon Medical with the production of its blood purification device. Thetwo companieshave previously2017/10/10
-
Allergan loses Restasis patent protections in federal court decisionAfter stirring up a tribal licensing controversy, Allergan has run into a patent setback with big-selling eye med Restasis. A federal judge invalidated exclusive protections for the drug—Allergan's2017/10/10
-
Lilly wards off another Alimta patent challenge, this time through IPREli Lilly has already foiled wannabe generic Alimta makers in court—and now it’s prevailed over one company taking the inter partes review route, too. The Indianapolis pharma has won an IPR challen2017/10/9
-
With new bill, Sen. McCaskill looks to end 'brazen' tribal licensing strategyOnly days after Sen. Claire McCaskill reached out to drug industry leadership with concerns over Allergan's tribal licensing deal, she's moving to shut down the "brazen loophole." The influential se2017/10/9
-
Court tosses Praluent ban, gives Sanofi and Regeneron a new trial in Amgen patent battleAn appeals court today tossed out a ban on Sanofi’s and Regeneron’s cholesterol drug Praluent and is giving the partners a second chance to prove they didn’t trample on Amgen patents in its developmen2017/9/30
-
Sanofi and Regeneron, seeking to shield Dupixent, lose first IPR try against AmgenTo defend against Amgen’s claim that Sanofi and Regeneron had infringed one of its patents with new atopic dermatitis rollout Dupixent, the development partners went the inter partes review route to t2017/9/30
-
Most new cancer meds haven't proved they can improve or extend lives: studySixty-eight cancer drug indications won European approval between 2009 and 2013—but most of them did so without showing they could extend or improve life, a new study shows. According toresultspubl2017/9/29
-
Pharma's legal challenge to U.K. cost clampdown gets shot downPharmaceutical companies, which have taken a hard stance against new cost-management strategies in England,have fallen short in an effort to block them with a legal challenge. The Association o2017/9/29